Pharmerging Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028
개요
세계 파머징 시장 규모는 2022년 11억 달러에 이르렀고, IMARC Group은 2022년부터 2028년까지 12.2%의 연평균 성장률(CAGR)을 보이며 2028년에는 22억 달러에 달할 것으로 예측했습니다.
제약 신흥국이란 의약품 시장에서의 지위가 낮고 빠르게 성장하고 있는 국가를 말합니다. 주요 신흥 제약시장으로는 중국, 인도, 브라질, 러시아, 남아프리카공화국, 멕시코, 인도네시아, 터키 등이 있습니다.
민간 병원 증가와 함께 의료비 지출이 증가함에 따라 현재 세계 의약품 신흥 시장의 성장을 주도하고 있습니다. 또한, 많은 만성 질환의 높은 유병률과 질병의 조기 발견 및 치료 절차에 대한 소비자의 인식이 높아짐에 따라 시장 성장에 더욱 박차를 가하고 있습니다. 또한 치매, 고혈압, 심부전 등 심각한 질병에 걸리기 쉬운 노인 인구 증가도 의약품 수요를 증가시키고 있습니다. 또한, 각국 정부의 만성질환 치료비 절감을 위한 정책 및 환급 제도 도입도 시장 성장을 가속하고 있습니다. 또한, 의약품 신흥국에서는 본인 부담금을 줄이기 위해 많은 보험을 제공하는 보험 회사가 증가하고 있으며, 이는 이들 국가의 의약품 수요를 더욱 증가시키고 있습니다. 이 외에도 생명공학, 면역학, 종양학 등의 분야에서 첨단 치료법 도입을 위한 광범위한 조사개발 활동에 대한 투자가 증가하고 있는 것도 시장 성장을 가속하고 있습니다.
본 보고서에서 다룬 주요 질문들
- 세계 파머징 시장은 지금까지 어떻게 성장해 왔으며, 향후 몇 년동안 어떻게 변화할 것인가?
- 주요 지역 시장은?
- 코로나19가 세계 파머징 시장에 미치는 영향은?
- 제품별 시장 분석은?
- 적응증별 시장 분석은?
- 유통 채널별 시장 분석은?
- 산업 가치사슬의 다양한 단계는?
- 시장의 주요 촉진요인과 과제는?
- 세계 파머징 시장의 구조와 주요 기업은?
- 시장 경쟁도는?
목차
제1장 서문
제2장 조사 범위와 조사 방법
- 조사 목적
- 이해관계자
- 데이터 소스
- 시장 추정
- 조사 방법
제3장 주요 요약
제4장 서론
제5장 세계의 파머징 시장
- 시장 개요
- 시장 실적
- COVID-19의 영향
- 시장 예측
제6장 시장 분석 : 제품별
제7장 시장 분석 : 적응증별
제8장 시장 분석 : 유통 채널별
제9장 시장 분석 : 국가별
- Tier I
- Tier II
- Tier III
- 아르헨티나
- 멕시코
- 폴란드
- 우크라이나
- 터키
- 사우디아라비아
- 이집트
- 알제리
- 나이지리아
- 태국
- 인도네시아
- 파키스탄
- 기타
제10장 SWOT 분석
제11장 밸류체인 분석
제12장 Porter의 Five Forces 분석
- 개요
- 바이어의 교섭력
- 공급 기업의 교섭력
- 경쟁 정도
- 신규 진출업체의 위협
- 대체품의 위협
제13장 경쟁 구도
- 시장 구조
- 주요 기업
- 주요 기업 개요
- Sanofi S.A.
- Pfizer Inc.
- AstraZeneca Plc.
- GlaxoSmithKline Plc.
- F. Hoffmann-La Roche AG(Roche AG)
- Eli Lilly and Company
- Johnson & Johnson
- Abbott Laboratories
- Novartis AG
- Teva Pharmaceutical Limited
LSH
Abstract
The global pharmerging market size reached US$ 1.1 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 2.2 Billion by 2028, exhibiting a growth rate (CAGR) of 12.2% during 2022-2028.
Pharmerging refers to a group of countries that hold low positioning in the pharmaceutical market but have a speedy growth. Some of the key pharmerging markets include China, India, Brazil, Russia, South Africa, Mexico, Indonesia, Turkey, etc.
The increasing healthcare expenditures along with the rising number of private hospitals are currently propelling the global pharmerging market growth. Additionally, the high prevalence of numerous chronic diseases and growing consumer awareness towards early disease detection and treatment procedures are further augmenting the market growth. Moreover, the increasing geriatric population, who are more prone to serious medical conditions, such as dementia, hypertension, cardiac failure, etc., is also bolstering the demand for pharmaceuticals. Additionally, the introduction of government policies and reimbursement schemes across various countries for reducing the cost of treatment for chronic diseases is also propelling the market growth. Moreover, the growing number of insurance companies in the pharmerging countries offering numerous insurance policies to decrease the out-of-the-pocket expenditures is further augmenting the demand of pharmaceuticals in these countries. Apart from this, the rising investments in extensive R&D activities in the fields of biotechnology, immunology, oncology, etc., for the introduction of advanced treatments are also catalyzing the market growth.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global pharmerging market report, along with forecasts at the global and country level from 2023-2028. Our report has categorized the market based on product, indication and distribution channel.
Breakup by Product:
Pharmaceuticals
Patented Prescription Drugs
Generic Prescription Drugs
OTC Drugs
Healthcare
Medical Devices
Clinical Diagnosis
Others
Breakup by Indication:
Lifestyle Diseases
Cancer and Autoimmune Diseases
Infectious Diseases
Others
Breakup by Distribution Channel:
Hospitals
Retail Pharmacies
Online Stores
Others
Breakup by Country:
Tier I
China
Tier II
India
Brazil
Russia
South Africa
Tier III
Argentina
Mexico
Poland
Ukraine
Turkey
Saudi Arabia
Egypt
Algeria
Nigeria
Thailand
Indonesia
Pakistan
Others
Competitive Landscape:
The competitive landscape of the industry has also been examined with some of the key players being Sanofi S.A., Pfizer Inc., AstraZeneca Plc, GlaxoSmithKline Plc, F. Hoffmann-La Roche AG (Roche AG), Eli Lilly and Company, Johnson & Johnson, Abbott Laboratories, Novartis AG and Teva Pharmaceutical Limited.
Key Questions Answered in This Report:
- How has the global pharmerging market performed so far and how will it perform in the coming years?
- What are the key regional markets?
- What is the impact of COVID-19 on the global pharmerging market?
- What is the breakup of the market based on the product?
- What is the breakup of the market based on the indication?
- What is the breakup of the market based on the distribution channel?
- What are the various stages in the value chain of the industry?
- What are the key driving factors and challenges in the market?
- What is the structure of the global pharmerging market and who are the key players?
- What is the degree of competition in the market?
Table of Contents
1 Preface
2 Scope and Methodology
- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
- 2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
- 4.1 Overview
- 4.2 Key Industry Trends
5 Global Pharmerging Market
- 5.1 Market Overview
- 5.2 Market Performance
- 5.3 Impact of COVID-19
- 5.4 Market Forecast
6 Market Breakup by Product
- 6.1 Pharmaceutical
- 6.1.1 Market Trends
- 6.1.2 Major Types
- 6.1.2.1 Patented Prescription Drugs
- 6.1.2.2 Generic Prescription Drugs
- 6.1.2.3 OTC Drugs
- 6.1.3 Market Forecast
- 6.2 Healthcare
- 6.2.1 Market Trends
- 6.2.2 Major Types
- 6.2.2.1 Medical Devices
- 6.2.2.2 Clinical Diagnosis
- 6.2.2.3 Others
- 6.2.3 Market Forecast
7 Market Breakup by Indication
- 7.1 Lifestyle Diseases
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
- 7.2 Cancer and Autoimmune Diseases
- 7.2.1 Market Trends
- 7.2.2 Market Forecast
- 7.3 Infectious Diseases
- 7.3.1 Market Trends
- 7.3.2 Market Forecast
- 7.4 Others
- 7.4.1 Market Trends
- 7.4.2 Market Forecast
8 Market Breakup by Distribution Channel
- 8.1 Hospitals
- 8.1.1 Market Trends
- 8.1.2 Market Forecast
- 8.2 Retail Pharmacies
- 8.2.1 Market Trends
- 8.2.2 Market Forecast
- 8.3 Online Stores
- 8.3.1 Market Trends
- 8.3.2 Market Forecast
- 8.4 Others
- 8.4.1 Market Trends
- 8.4.2 Market Forecast
9 Market Breakup by Country
- 9.1 Tier I
- 9.1.1 China
- 9.1.1.1 Market Trends
- 9.1.1.2 Market Forecast
- 9.2 Tier II
- 9.2.1 India
- 9.2.1.1 Market Trends
- 9.2.1.2 Market Forecast
- 9.2.2 Brazil
- 9.2.2.1 Market Trends
- 9.2.2.2 Market Forecast
- 9.2.3 Russia
- 9.2.3.1 Market Trends
- 9.2.3.2 Market Forecast
- 9.2.4 South Africa
- 9.2.4.1 Market Trends
- 9.2.4.2 Market Forecast
- 9.3 Tier III
- 9.3.1 Argentina
- 9.3.1.1 Market Trends
- 9.3.1.2 Market Forecast
- 9.3.2 Mexico
- 9.3.2.1 Market Trends
- 9.3.2.2 Market Forecast
- 9.3.3 Poland
- 9.3.3.1 Market Trends
- 9.3.3.2 Market Forecast
- 9.3.4 Ukraine
- 9.3.4.1 Market Trends
- 9.3.4.2 Market Forecast
- 9.3.5 Turkey
- 9.3.5.1 Market Trends
- 9.3.5.2 Market Forecast
- 9.3.6 Saudi Arabia
- 9.3.6.1 Market Trends
- 9.3.6.2 Market Forecast
- 9.3.7 Egypt
- 9.3.7.1 Market Trends
- 9.3.7.2 Market Forecast
- 9.3.8 Algeria
- 9.3.8.1 Market Trends
- 9.3.8.2 Market Forecast
- 9.3.9 Nigeria
- 9.3.9.1 Market Trends
- 9.3.9.2 Market Forecast
- 9.3.10 Thailand
- 9.3.10.1 Market Trends
- 9.3.10.2 Market Forecast
- 9.3.11 Indonesia
- 9.3.11.1 Market Trends
- 9.3.11.2 Market Forecast
- 9.3.12 Pakistan
- 9.3.12.1 Market Trends
- 9.3.12.2 Market Forecast
- 9.3.13 Others
- 9.3.13.1 Market Trends
- 9.3.13.2 Market Forecast
10 SWOT Analysis
- 10.1 Overview
- 10.2 Strengths
- 10.3 Weaknesses
- 10.4 Opportunities
- 10.5 Threats
11 Value Chain Analysis
12 Porters Five Forces Analysis
- 12.1 Overview
- 12.2 Bargaining Power of Buyers
- 12.3 Bargaining Power of Suppliers
- 12.4 Degree of Competition
- 12.5 Threat of New Entrants
- 12.6 Threat of Substitutes
13 Competitive Landscape
- 13.1 Market Structure
- 13.2 Key Players
- 13.3 Profiles of Key Players
- 13.3.1 Sanofi S.A.
- 13.3.1.1 Company Overview
- 13.3.1.2 Product Portfolio
- 13.3.1.3 Financials
- 13.3.1.4 SWOT Analysis
- 13.3.2 Pfizer Inc.
- 13.3.2.1 Company Overview
- 13.3.2.2 Product Portfolio
- 13.3.2.3 Financials
- 13.3.2.4 SWOT Analysis
- 13.3.3 AstraZeneca Plc.
- 13.3.3.1 Company Overview
- 13.3.3.2 Product Portfolio
- 13.3.3.3 Financials
- 13.3.3.4 SWOT Analysis
- 13.3.4 GlaxoSmithKline Plc.
- 13.3.4.1 Company Overview
- 13.3.4.2 Product Portfolio
- 13.3.4.3 Financials
- 13.3.4.4 SWOT Analysis
- 13.3.5 F. Hoffmann-La Roche AG (Roche AG)
- 13.3.5.1 Company Overview
- 13.3.5.2 Product Portfolio
- 13.3.5.3 Financials
- 13.3.5.4 SWOT Analysis
- 13.3.6 Eli Lilly and Company
- 13.3.6.1 Company Overview
- 13.3.6.2 Product Portfolio
- 13.3.6.3 Financials
- 13.3.6.4 SWOT Analysis
- 13.3.7 Johnson & Johnson
- 13.3.7.1 Company Overview
- 13.3.7.2 Product Portfolio
- 13.3.7.3 Financials
- 13.3.7.4 SWOT Analysis
- 13.3.8 Abbott Laboratories
- 13.3.8.1 Company Overview
- 13.3.8.2 Product Portfolio
- 13.3.8.3 Financials
- 13.3.8.4 SWOT Analysis
- 13.3.9 Novartis AG
- 13.3.9.1 Company Overview
- 13.3.9.2 Product Portfolio
- 13.3.9.3 Financials
- 13.3.9.4 SWOT Analysis
- 13.3.10 Teva Pharmaceutical Limited
- 13.3.10.1 Company Overview
- 13.3.10.2 Product Portfolio
- 13.3.10.3 Financial
- 13.3.10.4 SWOT Analysis
